Mutual of America Capital Management LLC purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 48,763 shares of the biopharmaceutical company's stock, valued at approximately $1,636,000. Mutual of America Capital Management LLC owned 0.06% of Xenon Pharmaceuticals at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in XENE. FMR LLC boosted its stake in shares of Xenon Pharmaceuticals by 8.8% in the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company's stock valued at $294,991,000 after purchasing an additional 607,606 shares during the period. Braidwell LP lifted its holdings in Xenon Pharmaceuticals by 7.6% in the 4th quarter. Braidwell LP now owns 2,913,964 shares of the biopharmaceutical company's stock worth $114,227,000 after buying an additional 206,709 shares in the last quarter. Janus Henderson Group PLC boosted its position in Xenon Pharmaceuticals by 12.3% in the 4th quarter. Janus Henderson Group PLC now owns 2,866,755 shares of the biopharmaceutical company's stock valued at $112,425,000 after buying an additional 314,363 shares during the last quarter. Polar Capital Holdings Plc boosted its position in Xenon Pharmaceuticals by 10.3% in the 4th quarter. Polar Capital Holdings Plc now owns 2,697,657 shares of the biopharmaceutical company's stock valued at $105,748,000 after buying an additional 253,012 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of Xenon Pharmaceuticals by 1.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,443,180 shares of the biopharmaceutical company's stock valued at $56,573,000 after acquiring an additional 18,445 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the company. Evercore ISI assumed coverage on Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price target on the stock. Wells Fargo & Company decreased their price target on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. The Goldman Sachs Group reduced their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Finally, Wall Street Zen downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. One analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $54.82.
View Our Latest Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Stock Down 0.6%
NASDAQ XENE traded down $0.18 during trading hours on Thursday, hitting $31.01. The company had a trading volume of 570,070 shares, compared to its average volume of 1,454,717. The business has a fifty day simple moving average of $31.50 and a 200-day simple moving average of $34.71. The firm has a market cap of $2.38 billion, a P/E ratio of -9.60 and a beta of 1.10. Xenon Pharmaceuticals Inc. has a fifty-two week low of $26.74 and a fifty-two week high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The firm had revenue of $7.50 million for the quarter, compared to analyst estimates of $1.64 million. During the same period in the previous year, the firm earned ($0.62) earnings per share. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access